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8-Hydroxy-2’-deoxyguanosine as a biomarker of oxidative stress in acute exacerbation of
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Background/aim: 8-Hydroxy-2’-deoxyguanosine (8-OHdG) is a biomarker of oxidative stress and has been implicated in many
diseases. The aim of this study was to investigate the clinical value of plasma 8-OHdG level in patients with acute exacerbation of chronic
obstructive pulmonary disease (AECOPD).
Materials and methods: A total of 154 subjects were enrolled in this study, including 20 healthy volunteers, 24 COPD patients in the
stable phase, and 110 AECOPD patients. Peripheral blood samples, demographic information, and clinical characteristics were collected
from all subjects at the time of being recruited into the study. Plasma 8-OHdG level was detected by enzyme-linked immunosorbent
assay.
Results: 8-OHdG was increased in patients with AECOPD compared to healthy subjects and patients with stable COPD, especially in
smokers. It also increased with the GOLD stage, mMRC grade, CAT score, and group level of combined COPD assessment. Additionally,
further analysis revealed that 8-OHdG was negatively correlated with FEV1, FEV1% predicted, and FEV1/FVC and positively correlated
with C-reactive protein, procalcitonin, and neutrophil CD64.
Conclusion: 8-OHdG is associated with spirometric severity, symptomatic severity, exacerbation risk, and inflammatory biomarkers in
AECOPD patients, suggesting it as a promising biomarker for reflecting disease severity and guiding the choice of optimal therapeutic
decision.
Key words: 8-Hydroxy-2’-deoxyguanosine, chronic obstructive pulmonary disease, acute exacerbation, oxidative stress

1. Introduction
Chronic obstructive pulmonary disease (COPD) is
characterized by progressive airflow limitation and
this pathologic change is poorly reversible. The airflow
limitation is associated with structural remodeling of
small airways, which can be precipitated by pollutants
such as toxic gases and harmful particulates (1,2). The
progression of COPD is variable. Some patients experience
relatively stable courses while others suffer frequent acute
exacerbations (3,4). The frequency of acute exacerbation
accelerates the decline of lung function, which not only
impairs the quality of life but also increases health care
utilization (1,5,6). Therefore, prevention, diagnosis, and
treatment of acute exacerbation are crucial for COPD
patients.
Cytokines and inflammatory factors are thought
to play an important role in the progression of COPD
(7,8) and act as marks of pathologic changes in the lungs

during disease progression. Acute exacerbation of COPD
(AECOPD) is associated with increased inflammation,
involving the accumulation of different inflammatory cells
and mediators in both lung tissue and circulation (9,10).
Besides, oxidative stress has also been recognized to play an
important role in the pathogenesis of COPD (11,12), and
the extent of oxidative stress can be estimated by several
biomarkers such as glutathione (GSH), total superoxide
dismutase (SOD), and malondialdehyde (MDA) (13,14).
Therefore, detection of these biomarkers may be helpful in
evaluating the severity of COPD.
8-Hydroxy-2’-deoxyguanosine
(8-OHdG),
continuously produced in living cells, is an end-product of
oxidative DNA damage. It is one of the most frequently
used biomarkers for evaluating oxidative stress. Previous
studies have observed elevated 8-OHdG in diabetes,
cancer, cardiovascular diseases, and stable COPD (15–17).
However, the level of 8-OHdG in AECOPD is still unclear.
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The purpose of our study was to explore plasma 8-OHdG
level in patients with AECOPD and its clinical value.
2. Materials and methods
2.1. General data
A total of 134 patients with COPD admitted to the Second
Affiliated Hospital of Nanjing Medical University between
September 2015 to August 2016 were included in this
study. At the same time, 20 healthy volunteers with normal
pulmonary function were enrolled in the study. Ethical
approval was given by the Ethics Committee of the Second
Affiliated Hospital of Nanjing Medical University and written
informed consent was obtained from all subjects.
The diagnosis and severity assessment of COPD were
based on the Global Initiatives for Chronic Obstructive Lung
Disease (GOLD) guidelines, and acute exacerbation was
defined as an acute worsening condition from stable state,
which presented with aggravated dyspnea, increased sputum
volume, and/or changed sputum color, or any combination of
these symptoms and requirement to alter the treatment plan
(5). Among the COPD patients included, 24 patients were in
a clinically stable phase and 110 patients underwent an acute
exacerbation. Epidemiological (age, sex, body mass index
(BMI)) and clinical data (blood pressure, smoking status, lung
function, home oxygen therapy, presence of comorbidities)
were collected at the time of recruitment. Pulmonary
function tests were conducted for a formal diagnosis of
COPD. The severity of the disease was categorized as GOLD
stage 1, mild (FEV1 ≥ 80%); GOLD stage 2, moderate (50% ≤
FEV1 < 80%); GOLD stage 3, severe (30% ≤ FEV1 < 50%); and
GOLD stage 4, very severe (FEV1 < 30%) (5). The Modified
British Medical Research Council (mMRC) questionnaire
(18) on breathlessness and the COPD Assessment Test (CAT)
score (19), a comprehensive assessment of symptoms, were
recorded for all COPD patients. According to the frequency
and severity of acute exacerbations within 1 year, the patients
were divided into a low-risk group (exacerbation ≤1 time
within 1 year and no hospitalization for exacerbation) and
high-risk group (exacerbations ≥2 times or exacerbation
≥1 time and hospitalization for exacerbation within 1 year).
Combined COPD assessment (A–D), which highlighted
both patient-reported outcomes and the importance of
exacerbation prevention in COPD management, was also
conducted. Smoking status in our study was based on selfreport. Exclusion criteria were as follows: patients with a
history of active pulmonary tuberculosis, bronchial asthma,
bronchiectasis, or cystic fibrosis, or receiving corticosteroids
or antibiotics treatment within 4 weeks. Patients with no
adequate plasma sample were also excluded.
2.2. Measurements of circulating 8-OHdG and other biomarkers
Peripheral venous blood samples were obtained at the
time of inclusion into the study. Serum procalcitonin
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(PCT) was quantified by immunofluorescent assay.
Serum C-reactive protein (CRP) was estimated by highsensitivity CRP assay. Serum CD64 index was measured
by flow cytometry using a commercial kit. Another 5 mL
of peripheral venous blood was collected and centrifuged
for 15 min (3000 rpm) at 4 °C within 1 h, and then the
supernatant was extracted and cryopreserved at –80 °C
for later 8-OHdG analysis. Plasma 8-OHdG concentration
was quantified by an enzyme-linked immunosorbent
assay (ELISA) kit (Calvin, Suzhou, China). All tests were
conducted according to the manufacturer’s instructions.
2.3. Statistical analysis
All statistical analyses were performed using SPSS 15.0
(SPSS Inc., Chicago, IL, USA). The continuous variables
were expressed as mean ± standard deviation (SD) and
discrete variables as counts (percentages). Student’s t-test
was used for comparison between two groups and ANOVA
was used for comparison among groups. The correlation
analyses between 8-OHdG and spirometry results, CRP,
PCT, and CD64 were analyzed using Pearson’s test. P <
0.05 was considered statistically significant.
3. Results
3.1. Demographic information and clinical characteristics
The demographic information and clinical characteristics
of the study population are summarized in the Table. There
were no significant differences in age, sex, or BMI among
the three groups (P > 0.05). Lung function tests were
recorded for all included subjects. In both COPD groups,
FEV1, FEV1% predicted, and FEV1/FVC were significantly
lower in comparison with those in healthy group. In
addition, blood pressure, smoking status and associated
comorbidities of all subjects are shown in the Table.
3.2. Plasma 8-OHdG levels were upregulated in AECOPD patients
Plasma 8-OHdG concentrations in healthy, stable COPD,
and AECOPD subjects are shown in Figure 1. We found
that 8-OHdG levels in AECOPD patients were increased
significantly in comparison with those in both stable
COPD patients and healthy subjects (0.45 ± 0.19 vs. 0.35 ±
0.10 ng/mL, P < 0.05; 0.45 ± 0.19 vs. 0.27 ± 0.18 ng/mL, P
< 0.05, respectively). However, no statistical difference of
8-OHdG was observed between stable COPD patients and
healthy subjects (P > 0.05).
3.3. 8-OHdG levels were further elevated in AECOPD
patients with smoking history
As shown in Figure 2, plasma 8-OHdG levels in patients
with AECOPD of different smoking statuses were
investigated. Only low levels of 8-OHdG were detected in
nonsmokers (0.37 ± 0.20 ng/mL). In contrast, high levels
of 8-OHdG were detected in both ex- and current smokers
(0.49 ± 0.17 ng/mL and 0.51 ± 0.18 ng/mL, respectively).
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Table. The demographic and clinical characteristics of study subjects.
Characteristics

Healthy subjects
(n = 20)

Stable COPD
(n = 24)

AECOPD
(n = 110)

Age (years)

64.34 ± 8.37

65.43 ± 6.90

68.21 ± 7.82

Sex (male/female)

13/7

13/11

62/48

BMI (kg/m2)

27.68 ± 5.53

24.22 ± 6.12

25.21 ± 5.31

Systolic blood pressure (mmHg)

129.4 ± 5.69

132.12 ± 8.96

152.05 ± 10.02*

Diastolic blood pressure (mmHg)

63.70 ± 2.69

60.65 ± 1.68

62.91 ± 4.18

Smoking status
Current smokers, n (%)

9 (45.00)

10 (41.67)

23 (20.91)

Ex-smokers, n (%)

4 (20.00)

3 (12.50)

41 (37.27)

Nonsmokers, n (%)

7 (35.00)

11 (45.83)

46 (41.82)

Smoking history (years)

42 ± 10.61

43 ± 18.06

45 ± 15.32

GLOD stage (1/2/3/4), n
FEV1 (L)

-

2/8/11/3

12/33/50/15

3.41 ± 0.30

2.15 ± 0.22*

1.86 ± 0.72*#

FEV1 % predicted

85 ± 8.85

59.81 ± 10.13*

48.63 ± 10.35*

FVC (L)

3.84 ± 0.57

3.63 ± 0.81

3.37 ± 0.69*

FEV1/FVC

0.88 ± 0.14

0.61 ± 0.14*

0.58 ± 0.22*

mMRC grade (0/1/2/3/4), n

-

4/6/7/5/2

9/21/40/35/5

CAT score

-

18.25 ± 5.61

20.75 ± 4.80

Low-risk, n (%)

-

8 (33.33)

34 (28.33)

High-risk, n (%)

Risk of exacerbations
-

16 (66.67)

86 (71.67)

Combined COPD assessment (A/B/C/D), n

-

4/5/8/7

15/28/36/31

Home oxygen therapy, n (%)

-

1 (4.17)

6 (5.45)

Cardiovascular diseases

-

16 (66.67)

86 (78.18)

Tumor

-

1 (4.17)

8 (7.27)

Comorbidities, n (%)

Pneumonia

-

1 (4.17)

42 (38.18)

Diabetes

-

6 (25.00)

25 (22.73)

Cerebrovascular disease

-

5 (20.83)

50 (45.45)

Liver disease

-

1 (4.17)

11 (10.00)

Renal disease

-

4 (16.67)

23 (20.91)

Data are presented as mean ± SD, unless otherwise indicated. * P < 0.05 compared with healthy group; # P < 0.05,
compared with stable COPD group.

However, there was no significant difference between exand current smokers in plasma 8-OHdG level (P = 0.64).
3.4. 8-OHdG level was associated with lung function
grade in AECOPD patients
The relationship between the level of 8-OHdG and
the severity of GOLD stage is shown in Figure 3. We found
that plasma 8-OHdG levels were significantly higher in
AECOPD patients with GOLD stage 3 and 4 than those
with GOLD stage 1 (0.48 ± 0.18 vs. 0.35 ± 0.19 ng/mL,

P < 0.05; 0.58 ± 0.19 vs. 0.35 ± 0.19 ng/mL, P < 0.05,
respectively) and 8-OHdG levels were higher in GOLD
stage 4 patients compared with those in GOLD stage 2
(0.58 ± 0.19 vs. 0.41 ± 0.18 ng/mL, P < 0.05).
3.5. 8-OHdG level was associated with the severity of
symptoms in AECOPD patients
The relationships between 8-OHdG and mMRC grade,
CAT score, and risk of exacerbation were explored. The
results showed that greater mMRC grade had a higher
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Figure 1. Levels of plasma 8-OHdG from healthy volunteers,
stable COPD patients, and AECOPD patients. ▲ P < 0.05
compared with healthy group; # P < 0.05 compared with stable
COPD group.

Figure 2. Levels of plasma 8-OHdG of AECOPD patients of
different smoking statuses. * P < 0.05 compared with nonsmokers;
“Non”, “Ex”, and “Current” represent nonsmokers, ex-smokers,
and current smokers, respectively.

trend with 8-OHdG level and the 8-OHdG level in the
mMRC grade 4 group was significantly higher than that in
the mMRC grade 1 group (P = 0.04) (Figure 4A). Positive
correlation was observed between 8-OHdG level and CAT
score (r = 0.206, P = 0.027) (Figure 4B). Higher level of
8-OHdG was observed in the high-risk group (high-risk
group vs. low-risk group, 0.45 ± 0.02 vs. 0.38 ± 0.03 ng/
mL), but no statistically significance was found (P =
0.701) (Figure 4C). The exploration of 8-OHdG level and
combined COPD assessment showed that 8-OHdG was
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Figure 3. Levels of plasma 8-OHdG in patients with AECOPD of
different GOLD stages. ▲ P < 0.05 compared with GOLD stage 1;
# P < 0.05 compared with GOLD stage 2.

markedly elevated in group D compared with those in
groups A and B (0.38 ± 0.05 ng/mL vs. 0.51 ± 0.03, 0.41 ±
0.03 vs. 0.51 ± 0.03 ng/mL, P < 0.05) (Figure 4D).
3.6. 8-OHdG in AECOPD patients was negatively correlated with spirometry results but positively correlated
with inflammatory markers
The correlations between 8-OHdG and spirometry results
in AECOPD patients were explored. In the univariate
analysis, negative correlations between 8-OHdG and FEV1
(r = –0.25, P = 0.007), FEV1% predicted (r = –0.22, P =
0.018), and FEV1/FVC (r = –0.242, P = 0.009) were observed
(Figures 5A–5C). The correlations between 8-OHdG and
inflammatory biomarkers were also explored. As shown in
Figures 5D–5F, there were positive correlations between
8-OHdG and CRP (r = 0.325, P = 0.000), PCT (r = 0.276, P
= 0.002), and CD64 (r = 0.423, P = 0.000).
4. Discussion
COPD is an aberrant inflammatory disease in airways,
pulmonary parenchyma, and vessels that results from
exposure to cigarette smoke, inhaled toxins, and
gene–environment interactions (5,8,9,18). Like other
chronic diseases, COPD presents with not only organspecific characteristics but also systemic manifestations
(20,21). Acute exacerbations are significant events in the
natural history of COPD, which contribute to tremendous
mortality all over the world. Oxidant/antioxidant
imbalance by lung cytotoxic mechanisms has been
demonstrated to play an important role in the pathogenesis
of COPD (22–24). Oxidative balance is necessary for
normal physiological functions, but inhaled pollutants
and other chemical factors can disturb this balance. Under
normal state, endogenous antioxidants, such as superoxide
dismutase, glutathione peroxidase, and catalase, protect
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Figure 4. Correlations between 8-OHdG levels and mMRC grade, CAT score, risk of exacerbations, and combined COPD assessment
in AECOPD patients. * P < 0.05 compared with mMRC grade 1; ▲ P < 0.05 compared with group A; # P < 0.05 compared with group B.

living organisms from oxidative damage (13). However,
excessive oxidative stress leads to mitochondrial DNA
damage as well as cellular injury (25).
8-OHdG, an oxidized form of guanine that is produced
from deoxyguanosine in DNA by reactive oxygen species
(ROS), was first reported in 1984 by Kasai et al. (15,26). The
level of 8-OHdG can be used for estimating oxidative DNA
damage. Previous studies have demonstrated that 8-OHdG
level increases in many diseases, such as diabetes, cancer,
and cardiovascular diseases (15–17). Our study showed
that plasma 8-OHdG levels were elevated in AECOPD
patients compared with those in stable COPD and healthy
subjects, but no statistical difference was found between
stable COPD patients and heathy subjects. This finding
suggests that oxidant stress increases during AECOPD and
application of 8-OHdG can be an appropriate approach
to diagnose AECOPD, monitor disease progression, and
guide treatment.

Increasing experimental evidence has proved that
smoking damages the lung tissue by the means of direct
toxicity to bronchial epithelial cells, oxidative damage, and
chronic inflammation (27,28). Cigarette smoke contains
high concentrations of free radicals and oxidants, which
are the major exogenous predisposing factors causing ROS
production as well as inflammation (29,30). According
to Asami et al. (31), 8-OHdG is elevated in the lungs
and peripheral leukocytes of smokers. In our study,
the plasma concentration of 8-OHdG was detected in
different smoking statuses during AECOPD. We found
that 8-OHdG was increased in smoking patients in
comparison with nonsmoking patients, indicating that
smoking exacerbated the oxidative damage in AECOPD.
Therefore, it is important to stop smoking to reduce
damage in lung tissue. However, no statistical difference
in 8-OHdG concentration was observed between ex- and
current smokers in AECOPD patients, suggesting that
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Figure 5. Correlations between 8-OHdG levels and spirometry results and inflammatory biomarkers in AECOPD patients.

oxidative DNA damage continued even after smoking
cessation (32).
Treatments of COPD are centered around patient
outcomes including spirometric severity, exacerbation
rate, and symptoms according to global strategies for
the diagnosis, management, and prevention of COPD
(5). However, the relationship between oxidative stress
and the disease severity of COPD is still uncertain.
Previous research has shown that the imbalance of
oxidants/antioxidants not only promotes inflammation
process, but also affects airway obstruction adversely
and accelerates decline in lung function (33). The
present results also provide important evidence for this
viewpoint. In our study, 8-OHdG level was positively
correlated with the severity of lung function, indicating
that excessive oxidative stress accelerated the decline
of lung function. This finding suggests that 8-OHdG
can be used for evaluating the spirometric severity of
AECOPD. Further study revealed that higher 8-OHdG
level was associated with greater mMRC grade, higher
CAT score, and higher group level of combined COPD
assessment. These findings suggest that 8-OHdG
can be used for evaluating symptomatic severity and
exacerbation risk in AECOPD patients.
To our knowledge, about half of the exacerbations of
COPD are precipitated by bacterial and viral infections
(34). Cytokines and inflammatory factors are available
for diagnosis and assessment of inflammatory process
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in AECOPD (34–37). A number of publications
have shown that CRP, PCT, and CD64 are sensitive
biomarkers for bacterial infections in AECOPD (37).
During inflammatory stimulation, their expressions are
rapidly upregulated. Brusselle et al. (38) reported that
enhanced oxidative stress causes increased systemic
inflammation in the airways during AECOPD. In our
study, significant positive correlations between plasma
8-OHdG level and inflammatory biomarkers were
observed, which confirmed the findings that oxidative
stress and systemic inflammation were strongly
interrelated processes during AECOPD (38–40). These
observations also indicate that combined measurements
of different biomarkers can be useful in understanding
and management of AECOPD patients.
Our study had some limitations. First, the numbers
of stable COPD patients and healthy volunteers were
insufficient, and larger number of subjects are needed
to draw robust conclusions. Second, we did not
conduct any study involving molecular mechanisms.
Lastly, we did not collet a second plasma sample
from AECOPD patients during hospitalization
or discharge; thus, the outcomes of patients with
AECOPD could not be assessed by 8-OHdG.
In conclusion, the present study investigated plasma
8-OHdG levels in AECOPD for the first time. The
8-OHdG level was found to increase in patients with
AECOPD and was higher in smokers. It was not only

LIU et al. / Turk J Med Sci
associated with spirometric severity, symptomatic
severity, and exacerbation risk, but was also positively
correlated with C-reactive protein, procalcitonin, and
neutrophil CD64. These findings suggest 8-OHdG as
a promising biomarker to guide the choice of optimal
therapeutic directions.
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